Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Botulinum Toxin Useful for Treating Masseteric Muscle Hypertrophy

By HospiMedica International staff writers
Posted on 12 Jan 2009
Injections of botulinum toxin (BoNT) for the treatment of mandibular swelling due to masseteric muscle hypertrophy (MMH) have proved an effective therapy, according to a new study.

Researchers at the second University of Naples (Italy) reported on a small case series that involved two men and three women ranging in age from 46 to 56 years. More...
All but one of the patients had bilateral hypertrophy of the masseter, and three of the patients had evidence of tooth grinding. The botulinum toxin (BoNT type A) was injected into the thickest portion of the hypertrophied muscle, as determined by palpation. The results showed that all of the patients experienced a marked improvement in their condition. One of the patients experienced a relapse, but was successfully treated with repeat injections. Satisfactory results were obtained 20 days, on average, after injection. The study was published in the November 2008 issue of The Journal of Craniofacial Surgery.

"The results of this study suggest that the use of botulinum toxin type A for contouring of the lower face can be established as a simple, predictable, alternative facial contouring procedure,” concluded lead author Raffaele Rauso, M.D., and colleagues of the department of head and neck pathology.

Botulinum toxin is a neurotoxic protein produced by the bacterium Clostridium botulinum, and is the most toxic protein known. Despite this, it is used in many parts of the world to treat muscle spasms and as a cosmetic treatment, since injecting muscles with minute quantities of BoNT decreases muscle activity by blocking the release of acetylcholine at the neuromuscular junction. This renders the muscle unable to contract for a period 3 to 4 months. The application of BoNT extends over many different indications, including strabismus, blepharospasm, hemifacial spasm, and others.

Related Links:
2nd University of Naples



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammography System (Analog)
MAM VENUS
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.